Search
PF-04620110
go.drugbank.com/drugs/DB14887InvestigationalPF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).
PF-04634817
go.drugbank.com/drugs/DB14955InvestigationalPF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).
PF-07038124
go.drugbank.com/drugs/DB19143InvestigationalPF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).
ATG-101
go.drugbank.com/drugs/DB17162InvestigationalATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
Synonyms: PD-L1/4-1BB bispecific antibodySacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalMetastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (...
Gotistobart
go.drugbank.com/drugs/DB19100InvestigationalGotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
DL-alpha tocopheryl acetate
go.drugbank.com/drugs/DB14477ApprovedMixtures: PR Natal 430, PR Natal 400PF-04457845
go.drugbank.com/drugs/DB12012InvestigationalPF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
PF-04418948
go.drugbank.com/drugs/DB12024InvestigationalPf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalwith group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates